A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer (Q46577596)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2007

edit

Language	Label	Description	Also known as
English	A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer	scientific article published in October 2007

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

title

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

main subject

phase II clinical trial

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author

Mark Rubin

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

Joseph Fontana

object named as

Joseph Fontana

series ordinal

2

0 references

George Wilding

series ordinal

5

object named as

George Wilding

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

Eric J Small

series ordinal

1

object named as

Eric J Small

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

author name string

Nizar Tannir

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

Robert S DiPaola

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

Renee Bailey Iacona

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

Fairooz F Kabbinavar

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

publication date

1 October 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

published in

BJU International

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

volume

100

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

page(s)

765-769

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

cites work

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1464-410X.2007.07121.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

PubMed publication ID

17822457

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17822457

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/17822457

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46577596&oldid=2186406856"